Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Proposes Fast-Track Approvals for Innovative Drugs

publication date: Jan 18, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China’s SFDA is considering far-reaching changes to its drug approval process. The proposals would replace the present system, which considers requests on a first-come, first-serve basis, with a system that prioritizes need. Innovative drug candidates, especially those that address unmet diseases, would be processed under new fast-track procedures. On the other hand, requests for approval of generic drugs that have multiple suppliers would be discouraged. In other words, the SFDA would respond much like the market itself, rather than treating each drugmaker request as equally important. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
Shanghai, China
April 14-15, 2015

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors